WestEnd Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

WestEnd Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9K	Buy	22 +3	+16%	+$1.33K	﹤0.01%	90
2026 Q1	$8.48K	Hold	19	–	–	﹤0.01%	85
2025 Q4	$8.61K	Buy	19 +12	+171%	+$5.17K	﹤0.01%	88
2025 Q3	$2.74K	Sell	7 -4	-36%	-$1.67K	﹤0.01%	132
2025 Q2	$4.9K	Buy	11 +1	+10%	+$461	﹤0.01%	104
2025 Q1	$4.85K	Buy	10 +7	+233%	+$3.26K	﹤0.01%	98
2024 Q4	$1.21K	Hold	3	–	–	﹤0.01%	119
2024 Q3	$1.4K	Hold	3	–	–	﹤0.01%	108
2024 Q2	$1.41K	Sell	3 -1	-25%	-$434	﹤0.01%	100
2024 Q1	$1.67K	Hold	4	–	–	﹤0.01%	94
2023 Q4	$1.63K	Hold	4	–	–	﹤0.01%	97
2023 Q3	$1.39K	Buy	+4	New	+$1.4K	﹤0.01%	93
2023 Q1	–	Sell	-3	Closed	-$900	–	110
2022 Q4	$866	Hold	3	–	–	﹤0.01%	106
2022 Q3	$1K	Hold	3	–	–	﹤0.01%	134
2022 Q2	$845	Buy	+3	New	+$803	﹤0.01%	117
2022 Q1	–	Sell	-2	Closed	-$475	–	147
2021 Q4	$439	Buy	+2	New	+$389	﹤0.01%	165
2021 Q3	–	Hold	0	–	–	–	167
2021 Q2	–	Hold	0	–	–	–	167

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

WestEnd Advisors's VRTX Position: Q2 2026 in Review

WestEnd Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2026, buying an estimated $1.33K and bringing the position to 22 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #90.

WestEnd Advisors first reported a position in VRTX in Q4 2021 and has held it in 16 quarters since. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

WestEnd Advisors held 22 shares of Vertex Pharmaceuticals worth $10.9K as of Q2 2026.
WestEnd Advisors bought 3 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
Vertex Pharmaceuticals made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #90 holding.
WestEnd Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.